| SMN1 — Survival Motor Neuron 1 | |
|---|---|
| Symbol | SMN1 |
| Full Name | Survival Motor Neuron 1 |
| Chromosome | 5q13.2 |
| NCBI Gene | 6606 |
| Ensembl | ENSG00000172062 |
| OMIM | 600354 |
| UniProt | Q16637 |
| Diseases | Spinal Muscular Atrophy |
| Expression | Motor neurons, Spinal cord, Widespread |
| Key Mutations | |
| Exon 7 deletion (homozygous), Point mutations in compound heterozygotes | |
Smn1 Survival Motor Neuron 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SMN1 (Survival Motor Neuron 1) is a gene located on chromosome 5q13.2 that encodes the survival motor neuron (SMN) protein, which is essential for spliceosome assembly and small nuclear ribonucleoprotein (snRNP) biogenesis. Mutations in SMN1 are the primary cause of [spinal muscular atrophy (SMA)--TEMP--/diseases)--FIX--, a devastating neuromuscular disorder. The gene is catalogued as NCBI Gene ID 6606 and OMIM 600354.
The SMN protein is ubiquitously expressed but is particularly critical for motor neuron survival. Its essential role in RNA splicing explains why loss of SMN function disproportionately affects motor neurons, which have particularly high spliceosomal demands[1].
SMN1 encodes the survival motor neuron (SMN) protein, a 294-amino acid protein with essential cellular functions:
Spliceosome Assembly: SMN is essential for assembling the major spliceosome, which processes over 95% of pre-mRNA transcripts[2].
snRNP Biogenesis: SMN complexes with SIP1, GEMIN2, GEMIN3, and GEMIN4 to form the SMN complex, which loads snRNPs (U1, U2, U4, U5, U6) onto the spliceosome.
Gem Formation: In the nucleus, SMN localizes to gemini of coiled bodies (gems), subnuclear structures near Cajal bodies that contain high concentrations of snRNPs.
SMN Complex Components:
The SMN complex orchestrates snRNP assembly through a multi-step process[3]:
Sm Ring Assembly: The SMN complex facilitates assembly of the Sm ring (SmB, SmD1, SmD2, SmD3, SmE, SmF, SmG) onto the snRNA.
snRNA Modification: Following Sm ring assembly, the snRNA undergoes 5' capping and 3' processing.
Nuclear Import: The assembled snRNP is imported into the nucleus.
Spliceosome Activation: In the nucleus, snRNPs join to form the spliceosome and participate in pre-mRNA splicing.
Motor neurons are particularly dependent on SMN function due to:
SMN1 mutations cause SMA, the leading genetic cause of infant mortality[4]:
| Type | Age of Onset | Severity | Life Expectancy |
|---|---|---|---|
| SMA Type I | 0-6 months | Severe | <2 years |
| SMA Type II | 6-18 months | Moderate | 2-30+ years |
| SMA Type III | >18 months | Mild | Adult |
| SMA Type IV | Adult | Very mild | Normal |
While SMN1 is not a primary ALS gene, there are connections:
Spinraza (Nusinersen): Antisense oligonucleotide that modifies SMN2 splicing to increase SMN protein production[5].
Onasemnogene abeparvovec (Zolgensma): Gene therapy delivering functional SMN1 gene.
Risdiplam: Small molecule that modulates SMN2 splicing.
Gene Therapy: AAV-delivered SMN1 to restore protein levels.
SMN is ubiquitously expressed with high levels in:
Expression data is available from the Allen Human Brain Atlas.
| Mutation | Type | Effect |
|---|---|---|
| Exon 7 deletion | Deletion | Homozygous - causes SMA |
| c.5delA | Frameshift | Loss of function |
| c.794delC | Frameshift | Loss of function |
| p.Gln136Lys | Missense | Partial function |
| p.Ser262Ile | Missense | Partial function |
The SMN complex is required for spliceosomal snRNP assembly. Cell, 1998. PMID: 9722917.
Spinal muscular atrophy: a new paradigm. Neuroscience, 2015. PMID: 26791737.
SMN deficiency in ALS: mechanisms and therapeutic targets. Neurobiol Aging, 2019. PMID: 31277954.
Nusinersen versus Sham Control in Infantile-Onset SMA. N Engl J Med, 2018. PMID: 29270178.
SMN1 and SMN2 in health and disease. Trends Genet, 2020. PMID: 32220276.
The study of Smn1 Survival Motor Neuron 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lefebvre S, et al. Identification and characterization of the spinal muscular atrophy gene. Cell. 1995;80(1):155-165. doi:10.1016/0092-8674(95)90460-3. ↩︎
Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nature Reviews Neuroscience. 2009;10(8):597-609. doi:10.1038/nrn2593. ↩︎
Monani UR. The spinal muscular atrophy gene: regulation and therapeutic targets. Human Molecular Genetics. 2005;14(R1):R119-R129. doi:10.1093/hmg/ddi163. ↩︎
Tisdale S, et al. SMN and spinal muscular atrophy. Brain Research. 2012;1462:40-50. doi:10.1016/j.brainres.2012.02.059. ↩︎
Liu Y, et al.N deficiency SM and motor neuron disease. Journal of Molecular Neuroscience. 2016;59(4):533-542. doi:10.1007/s12031-016-0746-3. ↩︎